Development of Combination Adjuvant for Efficient T Cell and Antibody Response Induction Against Protein Antigen

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2021 Aug 2

PMID 34339430

Citations 4

Authors

Yasunari Haseda

Lisa Munakata

Chiyo Kimura

Yumi Kinugasa-Katayama

Yasuko Mori

Ryo Suzuki

Taiki Aoshi

Affiliations

Soon will be listed here.

Abstract

Most current clinical vaccines work primarily by inducing the production of neutralizing antibodies against pathogens. Vaccine adjuvants that efficiently induce T cell responses to protein antigens need to be developed. In this study, we developed a new combination adjuvant consisting of 1,2-dioleoyl-3-trimethylammonium propane (DOTAP), D35, and an aluminum salt. Among the various combinations tested, the DOTAP/D35/aluminum salt adjuvant induced strong T cell and antibody responses against the model protein antigen with a single immunization. Adjuvant component and model antigen interaction studies in vitro also revealed that the strong mutual interactions among protein antigens and other components were one of the important factors for this efficient immune induction by the novel combination adjuvant. In addition, in vivo imaging of the antigen distribution suggested that the DOTAP component in the combination adjuvant formulation elicited transient antigen accumulation at the draining lymph nodes, possibly by antigen uptake DC migration. These results indicate the potential of the new combination adjuvant as a promising vaccine adjuvant candidate to treat infectious diseases and cancers.

Citing Articles

Enhancement of subunit vaccine delivery with zinc-carnosine coordination polymer through the addition of mannan.

Roque 3rd J, Lukesh N, Hendy D, Dixon T, Islam M, Ontiveros-Padilla L Int J Pharm. 2024; 656:124076.

PMID: 38569976 PMC: 11062752. DOI: 10.1016/j.ijpharm.2024.124076.

Poly(I:C) and R848 ligands show better adjuvanticity to induce B and T cell responses against the antigen(s).

Tandel N, Patel D, Thakkar M, Shah J, Tyagi R, Dalai S Heliyon. 2024; 10(5):e26887.

PMID: 38455541 PMC: 10918150. DOI: 10.1016/j.heliyon.2024.e26887.

R-DOTAP Cationic Lipid Nanoparticles Outperform Squalene-Based Adjuvant Systems in Elicitation of CD4 T Cells after Recombinant Influenza Hemagglutinin Vaccination.

Henson T, Richards K, Gandhapudi S, Woodward J, Sant A Viruses. 2023; 15(2).

PMID: 36851752 PMC: 9959843. DOI: 10.3390/v15020538.

The Current Landscape of mRNA Vaccines Against Viruses and Cancer-A Mini Review.

Ladak R, He A, Huang Y, Ding Y Front Immunol. 2022; 13:885371.

PMID: 35603213 PMC: 9120423. DOI: 10.3389/fimmu.2022.885371.

References

Hanagata N . Structure-dependent immunostimulatory effect of CpG oligodeoxynucleotides and their delivery system. Int J Nanomedicine. 2012; 7:2181-95. PMC: 3356174. DOI: 10.2147/IJN.S30197. View

Lu F, Boutselis I, Borch R, HogenEsch H . Control of antigen-binding to aluminum adjuvants and the immune response with a novel phosphonate linker. Vaccine. 2013; 31(40):4362-7. DOI: 10.1016/j.vaccine.2013.07.019. View

Klinman D . Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol. 2004; 4(4):249-58. DOI: 10.1038/nri1329. View

Gerner M, Torabi-Parizi P, Germain R . Strategically localized dendritic cells promote rapid T cell responses to lymph-borne particulate antigens. Immunity. 2015; 42(1):172-85. DOI: 10.1016/j.immuni.2014.12.024. View

Lonez C, Vandenbranden M, Ruysschaert J . Cationic lipids activate intracellular signaling pathways. Adv Drug Deliv Rev. 2012; 64(15):1749-58. DOI: 10.1016/j.addr.2012.05.009. View

Eickhoff S, Brewitz A, Gerner M, Klauschen F, Komander K, Hemmi H . Robust Anti-viral Immunity Requires Multiple Distinct T Cell-Dendritic Cell Interactions. Cell. 2015; 162(6):1322-37. PMC: 4567961. DOI: 10.1016/j.cell.2015.08.004. View

Rahimian S, Kleinovink J, Fransen M, Mezzanotte L, Gold H, Wisse P . Near-infrared labeled, ovalbumin loaded polymeric nanoparticles based on a hydrophilic polyester as model vaccine: In vivo tracking and evaluation of antigen-specific CD8(+) T cell immune response. Biomaterials. 2014; 37:469-77. DOI: 10.1016/j.biomaterials.2014.10.043. View

OHagan D, Valiante N . Recent advances in the discovery and delivery of vaccine adjuvants. Nat Rev Drug Discov. 2003; 2(9):727-35. PMC: 7097252. DOI: 10.1038/nrd1176. View

Simberg D, Weisman S, Talmon Y, Barenholz Y . DOTAP (and other cationic lipids): chemistry, biophysics, and transfection. Crit Rev Ther Drug Carrier Syst. 2005; 21(4):257-317. DOI: 10.1615/critrevtherdrugcarriersyst.v21.i4.10. View

10.

Segal L, Wouters S, Morelle D, Gautier G, Le Gal J, Martin T . Non-clinical safety and biodistribution of AS03-adjuvanted inactivated pandemic influenza vaccines. J Appl Toxicol. 2015; 35(12):1564-76. DOI: 10.1002/jat.3130. View

11.

Korsholm K, Hansen J, Karlsen K, Filskov J, Mikkelsen M, Lindenstrom T . Induction of CD8+ T-cell responses against subunit antigens by the novel cationic liposomal CAF09 adjuvant. Vaccine. 2014; 32(31):3927-35. DOI: 10.1016/j.vaccine.2014.05.050. View

12.

Gandhapudi S, Ward M, Bush J, Bedu-Addo F, Conn G, Woodward J . Antigen Priming with Enantiospecific Cationic Lipid Nanoparticles Induces Potent Antitumor CTL Responses through Novel Induction of a Type I IFN Response. J Immunol. 2019; 202(12):3524-3536. PMC: 9347971. DOI: 10.4049/jimmunol.1801634. View

13.

Regnier F, White J, Hem S . Contribution of electrostatic and hydrophobic interactions to the adsorption of proteins by aluminium-containing adjuvants. Vaccine. 1995; 13(1):41-4. DOI: 10.1016/0264-410x(95)80009-3. View

14.

Aoshi T, Haseda Y, Kobiyama K, Narita H, Sato H, Nankai H . Development of Nonaggregating Poly-A Tailed Immunostimulatory A/D Type CpG Oligodeoxynucleotides Applicable for Clinical Use. J Immunol Res. 2015; 2015:316364. PMC: 4562176. DOI: 10.1155/2015/316364. View

15.

Wang B, Hara K, Kawabata A, Nishimura M, Wakata A, Tjan L . Tetrameric glycoprotein complex gH/gL/gQ1/gQ2 is a promising vaccine candidate for human herpesvirus 6B. PLoS Pathog. 2020; 16(7):e1008609. PMC: 7377363. DOI: 10.1371/journal.ppat.1008609. View

16.

Lovgren Bengtsson K, Morein B, Osterhaus A . ISCOM technology-based Matrix M™ adjuvant: success in future vaccines relies on formulation. Expert Rev Vaccines. 2011; 10(4):401-3. DOI: 10.1586/erv.11.25. View

17.

Del Giudice G, Rappuoli R, Didierlaurent A . Correlates of adjuvanticity: A review on adjuvants in licensed vaccines. Semin Immunol. 2018; 39:14-21. DOI: 10.1016/j.smim.2018.05.001. View

18.

HogenEsch H, OHagan D, Fox C . Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want. NPJ Vaccines. 2018; 3:51. PMC: 6180056. DOI: 10.1038/s41541-018-0089-x. View

19.

de Titta A, Ballester M, Julier Z, Nembrini C, Jeanbart L, van der Vlies A . Nanoparticle conjugation of CpG enhances adjuvancy for cellular immunity and memory recall at low dose. Proc Natl Acad Sci U S A. 2013; 110(49):19902-7. PMC: 3856841. DOI: 10.1073/pnas.1313152110. View

20.

Foged C, Hansen J, Agger E . License to kill: Formulation requirements for optimal priming of CD8(+) CTL responses with particulate vaccine delivery systems. Eur J Pharm Sci. 2011; 45(4):482-91. DOI: 10.1016/j.ejps.2011.08.016. View